PT2582683T - Tratamento da gota e de hiperuricemia - Google Patents

Tratamento da gota e de hiperuricemia

Info

Publication number
PT2582683T
PT2582683T PT117963249T PT11796324T PT2582683T PT 2582683 T PT2582683 T PT 2582683T PT 117963249 T PT117963249 T PT 117963249T PT 11796324 T PT11796324 T PT 11796324T PT 2582683 T PT2582683 T PT 2582683T
Authority
PT
Portugal
Prior art keywords
hyperuricemia
drop
treatment
Prior art date
Application number
PT117963249T
Other languages
English (en)
Portuguese (pt)
Inventor
Girardet Jean-Luc
Miner Jeffrey
D Quart Barry
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2582683(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of PT2582683T publication Critical patent/PT2582683T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117963249T 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia PT2582683T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24

Publications (1)

Publication Number Publication Date
PT2582683T true PT2582683T (pt) 2018-05-25

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117963249T PT2582683T (pt) 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia

Country Status (19)

Country Link
US (3) US9216179B2 (https=)
EP (1) EP2582683B1 (https=)
JP (1) JP5964821B2 (https=)
CA (1) CA2802407C (https=)
CY (1) CY1120473T1 (https=)
DK (1) DK2582683T3 (https=)
ES (1) ES2670700T3 (https=)
HR (1) HRP20180780T1 (https=)
HU (1) HUE038265T2 (https=)
LT (1) LT2582683T (https=)
NO (1) NO2019008I1 (https=)
PL (1) PL2582683T3 (https=)
PT (1) PT2582683T (https=)
RS (1) RS57275B1 (https=)
SI (1) SI2582683T1 (https=)
SM (1) SMT201800266T1 (https=)
TR (1) TR201806828T4 (https=)
WO (1) WO2011159732A1 (https=)
ZA (1) ZA201300055B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
HUE038265T2 (hu) * 2010-06-15 2018-10-29 Ardea Biosciences Inc Köszvény és hiperurikémia kezelése
MY180138A (en) * 2011-11-03 2020-11-23 Ardea Biosciences Inc 3,4-di-substituted pyridine compound,methods of using and compositions comprising the same
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
CN114341120A (zh) * 2019-08-21 2022-04-12 国立大学法人东京大学 Abcc11抑制剂
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377937T3 (es) 2003-12-26 2012-04-03 Kissei Pharmaceutical Co., Ltd. Derivados de benzimidazol y usos médicos de los mismos
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
ES2374773T3 (es) 2004-08-25 2012-02-21 Ardea Biosciences, Inc. S-triazolil alfa-mercaptoacetanilidas como inhibidores de la transcriptasa inversa del vih.
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
AU2008206231A1 (en) 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
EA201100441A1 (ru) 2008-09-04 2011-10-31 Ардеа Биосайнсиз, Инк. Соединения для коррекции уровня мочевой кислоты и способы их применения
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CA2761335A1 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
EP2521716B1 (en) 2010-01-08 2015-12-30 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
HUE038265T2 (hu) * 2010-06-15 2018-10-29 Ardea Biosciences Inc Köszvény és hiperurikémia kezelése
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
ES2614914T3 (es) 2010-12-30 2017-06-02 Ardea Biosciences, Inc. Formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético y usos de las mismas
AU2012258860B2 (en) 2011-05-24 2015-12-03 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Also Published As

Publication number Publication date
WO2011159732A1 (en) 2011-12-22
SI2582683T1 (en) 2018-07-31
HRP20180780T1 (hr) 2018-07-13
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
US20160143889A1 (en) 2016-05-26
EP2582683B1 (en) 2018-03-21
US9216179B2 (en) 2015-12-22
EP2582683A1 (en) 2013-04-24
JP2013528650A (ja) 2013-07-11
TR201806828T4 (tr) 2018-06-21
ES2670700T3 (es) 2018-05-31
EP2582683A4 (en) 2014-04-30
JP5964821B2 (ja) 2016-08-03
CA2802407C (en) 2018-01-23
US20190015392A1 (en) 2019-01-17
HUE038265T2 (hu) 2018-10-29
RS57275B1 (sr) 2018-08-31
NO2019008I1 (no) 2019-02-19
DK2582683T3 (en) 2018-06-06
PL2582683T3 (pl) 2018-08-31
ZA201300055B (en) 2018-05-30
CA2802407A1 (en) 2011-12-22
SMT201800266T1 (it) 2018-07-17
CY1120473T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
PT2582683T (pt) Tratamento da gota e de hiperuricemia
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
BR112013002845A2 (pt) combinação de susbtâncias ativas
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
PT2616087T (pt) Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
EP2534248A4 (en) Selective reduction of allelic variants
EP2534262A4 (en) SELECTIVE REDUCTION OF ALL-VARIANTS
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
BR112013009496A2 (pt) artigos absorventes e métodos de fabricação dos mesmos
EP2785404A4 (en) CATHETER DEVICES AND METHOD THEREFOR
BR112012017441A2 (pt) compostos e métodos
BR112012026334A2 (pt) aparelho de cateter e introdutor de cateter
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
EP2549986A4 (en) MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
EP2489334A4 (en) MEDICAL STENT
PL2523678T3 (pl) Antagoniści Wnt i sposoby leczenia
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112014006291A2 (pt) composição e utilização da composição
BR112014031086A2 (pt) tratamento e prevenção de doenças cardiovasculares e trombose
BR112013002544A2 (pt) seção de armario e armario
BR112013009579A2 (pt) método e comprimido
SMT201600059B (it) Trattamento di infezioni da streptococco
HRP20181436T1 (hr) Postupak za primjenu nanočestica
EP2611440A4 (en) TREATMENT OF COCAINE
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER